Sacituzumab does not improve outcomes vs chemotherapy when used as the first treatment after endocrine therapy failure in HR+/HER2- advanced breast cancer, the ASCENT-07 trial finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results